Inhibikase Therapeutics (IKT) Other Non-Current Assets (2021 - 2026)
Inhibikase Therapeutics (IKT) reported Other Non-Current Assets of $1.0 million for Q1 2026, little changed quarter-over-quarter from $1.0 million in Q4 2025.
Inhibikase Therapeutics (IKT) Other Non-Current Assets (2021 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has 3 years of Other Non-Current Assets data on file, last reported at $1.0 million in Q1 2026.
- Other Non-Current Assets for Q1 2026 came in at $1.0 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $1.0 million (changed N/A YoY), and the FY2025 annual result was $1.0 million, changed N/A from the prior year.
- Other Non-Current Assets held at $1.0 million in Q1 2026 per IKT's latest filing, from $1.0 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $1.0 million in Q3 2025 and troughed at $1.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 60,000.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Inhibikase Therapeutics | 285.17 Mn | 114.80 Mn | - | 1.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.00 Mn |
| Dec 31, 2025 | 1.00 Mn |
| Sep 30, 2025 | 1.00 Mn |
| Mar 31, 2021 | 2,783.00 |